Literature DB >> 10775629

Cross-reactive T-helper responses in patients infected with different subtypes of human immunodeficiency virus type 1.

A C Leandersson1, G Gilljam, M Fredriksson, J Hinkula, A Alaeus, K Lidman, J Albert, G Bratt, E Sandström, B Wahren.   

Abstract

Immunization with a recombinant glycoprotein 160 envelope immunogen derived from a virus of genetic subtype B induced strong specific T-helper cell responses in asymptomatic human immunodeficiency virus (HIV) carriers infected with subtypes B to G. This indicates that the HIV-specific T-helper immunity, which is the basis for development of antibodies and cytotoxic T lymphocytes, can be improved by both homologous and heterologous antigens. It also suggests that a particular immunogen can be effective against many different HIV strains.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10775629      PMCID: PMC112013          DOI: 10.1128/jvi.74.10.4888-4890.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  CD28 costimulation and T lymphocyte proliferative responses in HIV-1 infection.

Authors:  M Carlesimo; O Pontesilli; A R Varani; M L Bernardi; A M Mazzone; R Rosso; E C Guerra; A Cassone; R Paganelli; F Aiuti
Journal:  Clin Exp Immunol       Date:  1997-09       Impact factor: 4.330

2.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

Review 3.  Cross-clade T cell recognition of HIV.1.

Authors:  F Gotch
Journal:  Curr Opin Immunol       Date:  1998-08       Impact factor: 7.486

4.  Most HIV-1 genetic subtypes have entered Sweden.

Authors:  A Alaeus; T Leitner; K Lidman; J Albert
Journal:  AIDS       Date:  1997-02       Impact factor: 4.177

5.  CD4+ T-cell recognition of diverse clade B HIV-1 isolates.

Authors:  M H Fernandez; S J Fidler; R J Pitman; J N Weber; A D Rees
Journal:  AIDS       Date:  1997-03       Impact factor: 4.177

6.  Induction of specific T-cell responses in HIV infection.

Authors:  A C Leandersson; G Bratt; J Hinkula; G Gilljam; P Cochaux; M Samson; E Sandström; B Wahren
Journal:  AIDS       Date:  1998-01-22       Impact factor: 4.177

7.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

Authors:  E S Rosenberg; J M Billingsley; A M Caliendo; S L Boswell; P E Sax; S A Kalams; B D Walker
Journal:  Science       Date:  1997-11-21       Impact factor: 47.728

8.  Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.

Authors:  R B Moss; W Giermakowska; P Lanza; J L Turner; M R Wallace; F C Jensen; G Theofan; S P Richieri; D J Carlo
Journal:  Viral Immunol       Date:  1997       Impact factor: 2.257

9.  A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).

Authors:  F T Valentine; S Kundu; P A Haslett; D Katzenstein; L Beckett; C Spino; M Borucki; M Vasquez; G Smith; J Korvick; J Kagan; T C Merigan
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

10.  High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors.

Authors:  C Rinaldo; X L Huang; Z F Fan; M Ding; L Beltz; A Logar; D Panicali; G Mazzara; J Liebmann; M Cottrill
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more
  2 in total

Review 1.  Therapeutic immunization for HIV.

Authors:  Lindvi Gudmundsdotter; Anna Sjödin; Ann-Charlotte Boström; Bo Hejdeman; Rebecca Theve-Palm; Annette Alaeus; Knut Lidman; Britta Wahren
Journal:  Springer Semin Immunopathol       Date:  2006-10-10

2.  Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters.

Authors:  Ali Azizi; David E Anderson; Masoud Ghorbani; Katrina Gee; Francisco Diaz-Mitoma
Journal:  BMC Immunol       Date:  2006-10-31       Impact factor: 3.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.